Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT 1: Relugolix Combination Therapy for Endometriosis Pain
NCT03204318Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of relugolix in endometriosis (3 arms), sponsored by Myovant Sciences. Primary endpoints: Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria at Week 24 and Percentage Of Participants Who Meet The Non-Menstrual Pelvic Pain Responder Criteria at Week 24. Started Dec 2017; status: completed.
02
Drugs
relugolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03204318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204318.